A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (TIVc) or in Embryonated Eggs (TIV), in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

The study is designed to evaluate the safety of TIVc or TIV vaccine in children 3 to < 18 years of age who are at risk of complications of influenza disease due to underlying diseases.

Inclusion Criteria:

• Individuals 3 to <18 years of age with underlying medical conditions that indicate an increased risk of complications from influenza infection.
• Further eligibility criteria may be discussed by contacting the site(s)

Exclusion Criteria:

• Individuals with any fatal prognosis of an underlying medical condition (<12 month life expectancy).
• Individuals hospitalized at the time of enrolment.
• Individuals with a history of any anaphylaxis, serious vaccine reactions, or hypersensitivity to any of the vaccine components.
• Further eligibility criteria may be discussed by contacting the site(s)